Griffin Securities’ Keith Markey on the Promise of RNAi and Synthetic Biologics

The Life Sciences Report: Keith, Griffin Securities’ portfolio seems weighted toward high-science, but high-risk, therapeutic ideas. How would you describe your investment philosophy? Keith Markey: We look for truly innovative products. These products come . . . → Read More: Griffin Securities’ Keith Markey on the Promise of RNAi and Synthetic Biologics Similar Articles: A Tour of Australian Biotechs with Morgans’ Scott Power Shortage of R&D at Big Pharma Creates Demand for Small Biotech: Joseph Pantginis Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.